Skip to main content
Clinical Trials/NCT06338033
NCT06338033
Completed
Not Applicable

Prognostic Study of Visceral Fat and Heart Failure With Preserved Ejection Fraction

Chongqing Medical University1 site in 1 country298 target enrollmentSeptember 19, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Preserved Ejection Fraction and Visceral Fat
Sponsor
Chongqing Medical University
Enrollment
298
Locations
1
Primary Endpoint
All-cause mortality
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Obesity and heart failure with preserved ejection fraction (HFpEF) have multiple pathologic associations that affect the prognosis of HFpEF. Chinese people are more prone to visceral obesity, resulting in varying degrees of true obesity in individuals with the same body mass index (BMI). There are no prognostic studies of VFA/BMI in the HFpEF population.

Detailed Description

A total of 298 patients with HFpEF who were hospitalized in the Department of Cardiovascular Medicine of the First Affiliated Hospital of Chongqing Medical University from September 2020 to August 2023 were included in this prospective cohort study.All patients were followed up on November 30, 2023.The primary endpoint of the study was all-cause mortality and secondary endpoints were rehospitalization for heart failure and composite endpoints of both.After a median follow-up of 564 days, a total of 30 (10.1%) patients died and 82 (27.5%) were rehospitalized for heart failure. Patients with HFpEF were categorized into two groups according to median VFA/BMI (VFA/BMI \<5.49; VFA/BMI ≥5.49).The aim of this study was to elucidate whether VFA/BMI has prognostic value in patients with HFpEF by Kaplan-Meier survival analysis and cox regression analysis.

Registry
clinicaltrials.gov
Start Date
September 19, 2020
End Date
November 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chongqing Medical University
Responsible Party
Principal Investigator
Principal Investigator

Dongying Zhang

Clinical Professor

Chongqing Medical University

Eligibility Criteria

Inclusion Criteria

  • Adule aged≥18 years old;
  • Diagnosed with HFpEF.
  • Diagnostic criteria including:
  • left ventricular ejection fraction ≥50%;
  • with signs and/or symptoms of heart failure;
  • Sinus rhythm:BNP≥35pg/mL and/or NT-proBNP≥125pg/mL;Atrial fibrillation rhythm:BNP≥105pg/mL and/or NT-proBNP≥365pg/mL;
  • at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction.

Exclusion Criteria

  • Age ≤18 years;
  • malignant tumor;
  • comorbid severe hepatic and/or renal insufficiency;
  • lost to follow-up.

Outcomes

Primary Outcomes

All-cause mortality

Time Frame: November 30, 2023

All-cause mortality

Secondary Outcomes

  • Rehospitalization for heart failure(November 30, 2023)

Study Sites (1)

Loading locations...

Similar Trials